Dr. Jeffrey S. Miller to Present on Progress of GTB-3550 TriKE™ Phase I Trial Accompanying GT Biopharma's Company Presentation at Raymond James Human Health Innovation Conference June 21, 2021
GT Biopharma to Host Interim GTB-3550 TriKE™ Data Review Call with Dr. Jeffrey S. Miller on May 19, 2021 at 4:00 PM ET May 18, 2021
GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Trial And Solid Tumor TriKE™ Product Candidates May 12, 2021
GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S. Miller, M.D. to Consulting Chief Scientific Officer April 26, 2021
GT Biopharma Announces GTB-3550 TriKE™ Monotherapy Rescues and Restores NK Cell Immune Surveillance in Relapsed/Refractory AML and MDS Cancer Patients April 12, 2021
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial April 8, 2021
